Astrid Pharma Corp
A next-generation nanocapsid delivery platform for precision medicine
BioCapZ combines a modular protein-based delivery system with AI-guided design to unlock targeted therapeutics, vaccines, and image-guided tumor treatment.
One platform. Three converging capabilities.
BioCapZ Nanocapsid Platform
A versatile, protein-based delivery system engineered to carry virtually any therapeutic payload — stable at ambient temperature and designed for needle-free administration.
AI-Guided Design
Computational peptide and antigen design for highly targeted cancer therapeutics and vaccines, accelerating development from in silico concept to candidate.
AI-Guided Hyperthermia Treatment
Imaging-guided, machine-learning-assisted tumor treatment with real-time feedback — precision hyperthermia with minimal impact to healthy tissue.
AI-Guided Precision Medicine
BioCapZ pairs its nanocapsid delivery platform with AI-driven, in silico design to accelerate development of both cancer therapeutics and vaccines.
Cancer targeting
AI-guided peptide design computationally engineers therapeutic peptides to precisely target tumor cells, speeding development while improving specificity.
Vaccine design
The same in silico approach engineers antigens to optimize MHC Class I & II immune presentation, driving stronger, more durable immune protection.
Pandemic-ready by design
Because BioCapZ decouples the antigen from the delivery vehicle, a new antigen can be swapped into the platform without redesigning the whole system — a "sequence-to-sleeve" approach that allows near-instantaneous updates in response to emerging variants or a novel pathogen ("Disease X"). Combined with the platform's ambient-temperature stability and needle-free, self-administered format, this means a vaccine response can move from design to scalable, cold-chain-free distribution far faster than conventional approaches — critical for outbreak and pandemic preparedness.
Let's build the future of precision medicine together
We welcome conversations with investors, pharma partners, and research institutions.
Contact Us